Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Adam J Olszewski, MD, Peter Barth, MD, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 709.

https://doi.org/10.1182/blood-2018-99-110739

Published: 2018

Journal Articles

Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma

Marianne Razavi, PhD, Rahul Mhaskar, MPH, Benjamin Djulbegovic, MD

Blood (2018) 132 (Supplement 1): 5638.

https://doi.org/10.1182/blood-2018-99-116976

Published: 2018

Journal Articles

Influences of Mycophenolate Mofetil and Cyclosporine-a on the Ex Vivo-Expanded Vδ2 T Cells

Haitao Gao, Jiangying Liu, Xiaoyu Wang, Xiao-Jun Huang

Blood (2018) 132 (Supplement 1): 5686.

https://doi.org/10.1182/blood-2018-99-116357

Published: 2018

Journal Articles

Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States

Smith Giri, MBBS, Weiwei Zhu, MPH, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD MS, Scott F Huntington, MDMPH

Blood (2018) 132 (Supplement 1): 978.

https://doi.org/10.1182/blood-2018-99-119791

Published: 2018

Journal Articles

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States

Leah J McGrath, PhD, Rohini K Hernandez, PhD, Robert Overman, PhD, Diane Reams, Pharm.D., MPH, Alexander Liede, MSc, PhD, M. Alan Brookhart, PhD

Blood (2017) 130 (Supplement 1): 534.

https://doi.org/10.1182/blood.V130.Suppl_1.534.534

Published: 2017

Journal Articles

Unusual Long Term Remission in Multiple Myeloma Using Conventional Therapy Combined with Danazol

Matthew P Salzberg, MD, Pamela B. Dudkiewicz, DNP, ARNP, Lawrence L. Horstman, BS, Wenche Jy, PhD, Yeon S. Ahn, MD

Blood (2017) 130 (Supplement 1): 5423.

https://doi.org/10.1182/blood.V130.Suppl_1.5423.5423

Published: 2017

Journal Articles

Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data

Christopher Kim, Rohini K. Hernandez, PhD, Paul C Cheng, MD PhD, Jeremy Smith, Lori Cyprien, Alexander Liede, BSc, MSc, PhD

Blood (2016) 128 (22): 2364.

https://doi.org/10.1182/blood.V128.22.2364.2364

Published: 2016

Journal Articles

Bisphosphonate Therapy in Langerhans Cell Histiocytosis: An International Retrospective Descriptive Study

Deepak Chellapandian, MD MBBS, Polyzois Makras, MD PhD, Gregory Kaltsas, MD PhD, Cor van den Bos, MDPhD, Anne-Sophie Carret, MD, Sheila Weitzman, MB BCh, FRCP, Maarten Egeler, MD PhD, Oussama Abla, MD

Blood (2015) 126 (23): 2209.

https://doi.org/10.1182/blood.V126.23.2209.2209

Published: 2015

Journal Articles

Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data

Yi Qian, PhD, Debajyoti Bhowmik, B.Pharm, PhD, Nandita Kachru, MS, Rohini K. Hernandez, PhD, Paul Cheng, MD PhD, Alexander Liede, BSc, MSc, PhD

Blood (2015) 126 (23): 4501.

https://doi.org/10.1182/blood.V126.23.4501.4501

Published: 2015

Journal Articles

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Gabriella Hobbs, MD, Rivka Litvin, Jihae Ahn, Anna Sophia Mckenney, Michael J. Mauro, MD, Martin S Tallman, MD, Ellin Berman, MD, Mark Lawrence Heaney, MD PhD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4075.

https://doi.org/10.1182/blood.V126.23.4075.4075

Published: 2015

Journal Articles

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Marita Westhrin, MSc, Siv Helen Moen, PhD, Toril Holien, PhD, Oddrun Elise Olsen, MSc, Anne Kærsgaard Mylin, MDhD, Peter Gimsing, MD PhD, Ingemar Turesson, MD PhD, Anders Waage, MD PhD, Therese Standal, PhD

Blood (2014) 124 (21): 2065.

https://doi.org/10.1182/blood.V124.21.2065.2065

Published: 2014

Journal Articles

Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma

Kristen M. Sanfilippo, MD, Brian F Gage, MD, MSc, Suhong Luo, MPH, Ravi Vij, MD, Michael H. Tomasson, MD, Katherine N Weilbaecher, MD, Kenneth R. Carson, MD

Blood (2013) 122 (21): 3182.

https://doi.org/10.1182/blood.V122.21.3182.3182

Published: 2013

Journal Articles

UK Patient Perspectives of Bisphosphonate Treatment Highlight a Lack of Knowledge On Therapeutic Benefits and Strong Preferences for Choice and Location of Treatment

Eric Low, Kate E Morgan

Blood (2012) 120 (21): 2074.

https://doi.org/10.1182/blood.V120.21.2074.2074

Published: 2012

Journal Articles

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Chirayu Patel, Andrew Yee, Tyler A. Scullen, Neeharika Nemani, Loredana Santo, Anuj Mahindra, Paul G. Richardson, MD, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Robert Schlossman, MD, Kenneth C. Anderson, Nikhil C Munshi, MD, Noopur Raje

Blood (2012) 120 (21): 3965.

https://doi.org/10.1182/blood.V120.21.3965.3965

Published: 2012

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

Journal Articles

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Ashraf Z. Badros, MD, Sunita Philip, Patricia Lesho, Dianna Weikel, Olga Goloubeva, Mariola Sadowska, Rena Lapidus, PhD, Lisa Hester, Todd Milliron, Timothy Meiller

Blood (2012) 120 (21): 4245.

https://doi.org/10.1182/blood.V120.21.4245.4245

Published: 2012

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Noopur Raje, MD, Robert Vescio, MD, Charles W. Montgomery, MD, Ramakrishnan Parameswaran, MD, Diep Tran, MS, Ghulam Warsi, PhD, Eliza Argonza-Aviles, RN, MSHS, Solveig G. Ericson, MD- PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 5122.

https://doi.org/10.1182/blood.V118.21.5122.5122

Published: 2011

Journal Articles

Redirecting αβT cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor

Victoria Marcu-Malina, Sabine Heijhuurs, Marit van Buuren, Linda Hartkamp, Susanne Strand, Zsolt Sebestyen, Kirsten Scholten, Anton Martens, Jürgen Kuball

Blood (2011) 118 (1): 50–59.

https://doi.org/10.1182/blood-2010-12-325993

Published: 2011

Includes: Supplemental data

Journal Articles

Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ.

Prakash Varadarajan, MD, Juan Toro, Robert M. Craig, Deanna Schneider, Ju-Hsien Chao, David Haile, Cesar O. Freytes, MD

Blood (2010) 116 (21): 1314.

https://doi.org/10.1182/blood.V116.21.1314.1314

Published: 2010

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Blood (2010) 116 (21): 2971.

https://doi.org/10.1182/blood.V116.21.2971.2971

Published: 2010

NARROW

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma

Influences of Mycophenolate Mofetil and Cyclosporine-a on the Ex Vivo-Expanded Vδ2 T Cells

Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States

Unusual Long Term Remission in Multiple Myeloma Using Conventional Therapy Combined with Danazol

Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data

Bisphosphonate Therapy in Langerhans Cell Histiocytosis: An International Retrospective Descriptive Study

Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma

UK Patient Perspectives of Bisphosphonate Treatment Highlight a Lack of Knowledge On Therapeutic Benefits and Strong Preferences for Choice and Location of Treatment

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Redirecting αβT cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor

Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ.

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only